Featuring an interview with Dr Matthew Matasar, including the following topics:
- Rationale for the evaluation of anti-CD20 x CD3 bispecific antibodies in the treatment of non-Hodgkin lymphoma (NHL) (0:00)
- Incidence, severity and time course of cytokine release syndrome, neurotoxicity/ICANS and other adverse events associated with bispecific antibodies; recommended mitigation and management protocols (4:39)
- Activity of and similarities and differences among the various bispecific antibodies for NHL (12:20)
- Eligibility, efficacy and durability of response with mosunetuzumab, glofitamab, epcoritamab and odronextamab; ongoing and planned evaluations of bispecific antibodies alone and in combination with other systemic therapies (19:18)
- Optimal integration of bispecific antibody platforms into treatment algorithms for patients with NHL (32:12)
- Emerging results with bispecific antibodies for mantle cell lymphoma and chronic lymphocytic leukemia (41:51)
CME information and select publications
Research To Practice | Oncology Videos